Table 1.
CON | FTLD‐TDP | FTLD‐Tau | AD | DLB | |
---|---|---|---|---|---|
Cohort 1 (Emory + Milan) | |||||
n (M/F) | 29 (14/15) | 30 (18/12) | 20 (13/7) | 30 (15/15) | 29 (15/14) |
Age, years (mean ± SD) | 62 (15) | 66 (7) | 65 (10) | 69 (8) | 68 (8) |
n (Emory/Milan) | 20/9 | 20/10 | 20/0 | 20/10 | 20/9 |
Aβ 1–42 (pg/mL) | 408 (307)a,c, d,e | 230 (452)b | 176 (101)b | 218 (211)b | 298 (279)b |
t‐Tau (pg/mL) | 46 (36)a | 78 (114)a | 43 (35)a | 171 (156)b,c,d,e | 43 (199)a |
pTau (pg/mL) | 18 (12)a,e | 23 (21)a,e | 18 (14)a | 72 (46)b,c,d,e | 33 (19)a,b,c |
FTLD subgroups | 8 autopsy | 2 autopsy | |||
15 mutations | 2 mutations | ||||
7 FTLD‐ALS | 1 family history | ||||
10 PSP | |||||
5 CBS | |||||
Cohort 2 (VUmc + ErasmusMC) | |||||
n (M/F) | 59 (32/27) | 42 (23/19) | 50 (26/24) | 17 (9/8) | 20 (17/3) |
Age, years (mean ± SD) | 59 (10) | 60(8) | 64 (9) | 64 (6) | 63 (5) |
Aβ 1–42 (pg/mL) | 983 (342)a,c, d,e | 874 (328)a,b | 795 (335)a,b | 461 (137)b,c,d,e | 648 (483)a,b |
t‐Tau (pg/mL) | 249 (106)a,c | 353 (137)a,b | 290 (182)a | 622 (237)b,c,d,e | 299 (118)a |
pTau (pg/mL) | 45 (20)a | 38 (15)a,e | 39 (21)a | 84 (26)b,c,d,e | 53 (24)a |
FTLD subgroups | 15 autopsy | 3 autopsy | |||
21 mutations | 5 mutations | ||||
6 FTLD‐ALS | 22 PSP | ||||
20 CBS |
CON, nondemented controls; FTLD, frontotemporal lobar degeneration; AD, Alzheimer's disease; DLB, dementia with Lewy body; PSP, progressive supranuclear palsy; CBS, corticobasal syndrome; n, number of cases; M, Male; F, female.
P < 0.05 compared to AD.
P < 0.05 compared to CON.
P < 0.05 compared to FTLD‐TDP.
P < 0.05 compared to FTLD‐Tau.
P < 0.05 compared to DLB.